Rifampin & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine and midazolam + rifapentine and midazolam
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Trial Timeline
Apr 1, 2010 → Mar 1, 2011
NCT ID
NCT01162486About Rifampin & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine and midazolam + rifapentine and midazolam
Rifampin & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine and midazolam + rifapentine and midazolam is a phase 1 stage product being developed by Sanofi for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01162486. Target conditions include Tuberculosis, Tuberculosis, Pulmonary.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01162486 | Phase 1 | Completed |
Competing Products
20 competing products in Tuberculosis